Home
Conditions
Lymphoproliferative Disorders

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,031 public trials 2,028 recruiting studies

Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Active, Not Recruiting

Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)

NCT04439123

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +22 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, Not Recruiting

Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

NCT04126200

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: GSK Investigational Site Atlanta, Georgia, United States

GSK Investigational Site Indianapolis, Indiana, United States

GSK Investigational Site Boston, Massachusetts, United States

GSK Investigational Site Grand Rapids, Michigan, United States

View all 38 locations

View Trial Details

Active, Not Recruiting

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

NCT04872790

Conditions: B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Burkitt Lymphoma, +23 more
Locations: OHSU Knight Cancer Institute Portland, Oregon, United States

View Trial Details

Active, Not Recruiting

Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)

NCT04439175

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +22 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, Not Recruiting

A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant

NCT04872595

Conditions: Acute Lymphoid Leukemia (ALL), Acute Myeloid Leukemia (AML), Bone Marrow Diseases, +15 more
Locations: Memorial Sloan Kettering Cancer Center New York, United States

View Trial Details

Active, Not Recruiting

Obinutuzumab in Marginal Zone Lymphoma

NCT03322865

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: Augusta-Kranken-Anstalt gGmbH Bochum, Germany

University Hospital Essen Essen, Germany

Universitätsklinikum Freiburg Freiburg im Breisgau, Germany

Universitätsmedizin Georg-August-University Göttingen, Germany

View Trial Details

Active, Not Recruiting

Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)

NCT06390852

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +19 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, Not Recruiting

A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China

NCT07226752

Conditions: Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations: Affiliated Hospital of Hebei University Baoding, China

Beijing Cancer Hospital Beijing, China

Beijing Tongren Hospital, Capital Medical University Beijing, China

Peking University Third Hospital Beijing, China

View all 23 locations

View Trial Details

Active, Not Recruiting

Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders

NCT01177527

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +23 more
Locations: Dana-Farber Cancer Institute Boston, Massachusetts, United States

View Trial Details

Active, Not Recruiting

Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma

NCT06112847

Conditions: Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations: City of Hope Medical Center Duarte, California, United States

City of Hope at Irvine Lennar Irvine, California, United States

View Trial Details

Lymphoproliferative Disorders

Lymphoproliferative Disorders trial results

Related conditions